David J Graham

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. doi request reprint Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
    David J Graham
    Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Room 4314, Silver Spring, MD 20993 0002, USA
    JAMA 304:411-8. 2010
  2. doi request reprint Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone
    David J Graham
    Office of Epidemiology and Surveillance, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Mov Disord 28:490-7. 2013
  3. ncbi request reprint Troglitazone-induced liver failure: a case study
    David J Graham
    Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, HFD 400, Room 15B 32, Rockville, MD 20857, USA
    Am J Med 114:299-306. 2003
  4. doi request reprint Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs
    Tarek A Hammad
    Office of Surveillance and Epidemiology, Food and Drug Administration, Silver Spring, MD 20993 0002, USA
    Pharmacoepidemiol Drug Saf 17:315-21. 2008
  5. ncbi request reprint Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
    David J Graham
    Office of of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    JAMA 292:2585-90. 2004
  6. ncbi request reprint Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey
    Stephen R Benoit
    Food and Drug Administration, Rockville, Maryland, USA
    Eur J Cardiovasc Prev Rehabil 12:363-8. 2005
  7. ncbi request reprint Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone
    David J Graham
    Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA
    Am J Gastroenterol 98:175-9. 2003
  8. ncbi request reprint Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study
    David J Graham
    Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA
    Lancet 365:475-81. 2005
  9. ncbi request reprint Peripheral neuropathy in patients treated with leflunomide
    Renan A Bonnel
    Office of Drug Safety, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD 20857, USA
    Clin Pharmacol Ther 75:580-5. 2004

Detail Information

Publications9

  1. doi request reprint Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
    David J Graham
    Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Room 4314, Silver Spring, MD 20993 0002, USA
    JAMA 304:411-8. 2010
    ..Studies have suggested that the use of rosiglitazone may be associated with an increased risk of serious cardiovascular events compared with other treatments for type 2 diabetes...
  2. doi request reprint Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone
    David J Graham
    Office of Epidemiology and Surveillance, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Mov Disord 28:490-7. 2013
    ..09; 95% CI, 0.98-4.45) or absence (HR, 0.51; 95% CI, 0.27-0.95) of advanced PD-related morbidities (P value for interaction=0.004). Entacapone was not associated with an increased risk of AMI, stroke, or death in elderly patients with PD...
  3. ncbi request reprint Troglitazone-induced liver failure: a case study
    David J Graham
    Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, HFD 400, Room 15B 32, Rockville, MD 20857, USA
    Am J Med 114:299-306. 2003
    ..We evaluated the clinical features of all cases reported to the Food and Drug Administration and estimated the duration and magnitude of the risk of liver failure associated with continued use of the drug...
  4. doi request reprint Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs
    Tarek A Hammad
    Office of Surveillance and Epidemiology, Food and Drug Administration, Silver Spring, MD 20993 0002, USA
    Pharmacoepidemiol Drug Saf 17:315-21. 2008
    ....
  5. ncbi request reprint Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
    David J Graham
    Office of of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    JAMA 292:2585-90. 2004
    ..Lipid-lowering agents are widely prescribed in the United States. Reliable estimates of rhabdomyolysis risk with various lipid-lowering agents are not available...
  6. ncbi request reprint Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey
    Stephen R Benoit
    Food and Drug Administration, Rockville, Maryland, USA
    Eur J Cardiovasc Prev Rehabil 12:363-8. 2005
    ..Although research exists on the relationship between QT prolongation and clinical outcome, few studies have described risk factors for prolonged QT interval in the general population...
  7. ncbi request reprint Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone
    David J Graham
    Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA
    Am J Gastroenterol 98:175-9. 2003
    ..This study was conducted to estimate the incidence rates of hospitalized idiopathic acute liver injury and ALF among troglitazone-treated patients...
  8. ncbi request reprint Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study
    David J Graham
    Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA
    Lancet 365:475-81. 2005
    ....
  9. ncbi request reprint Peripheral neuropathy in patients treated with leflunomide
    Renan A Bonnel
    Office of Drug Safety, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD 20857, USA
    Clin Pharmacol Ther 75:580-5. 2004
    ..Our objective was to describe the clinical features, time course, and outcome of new-onset peripheral neuropathy occurring in patients treated with leflunomide...